PURPOSE: To demonstrate that OKN007, a disulfonyl derivative of phenyl-tert-butyl nitrone (PBN), has anti-glioma activity in the clinically relevant C6 rat glioma model using multi-parametric magnetic resonance imaging. MATERIALS AND METHODS: Twenty-one rats were intracerebrally implanted with C6 cells and administered OKN007 or kept as controls. Animals were monitored with MRI at 7 Tesla (T), using morphologic, diffusion-weighted and perfusion imaging, followed by histology and Western blots of angiogenesis and inflammatory markers. RESULTS: OKN007 was found to decrease tumor volumes and increase survival. The glioma tissues of OKN007-treated rats were found to have longitudinal apparent diffusion coefficients (ADC(z)) of 0.76 +/- 0.06 x 10(-3) mm(2)/s, similar to the contralateral tissue and significantly smaller than untreated gliomas (0.97 +/- 0.13 x 10(-3) mm(2)/s). They had higher perfusion rates (66 +/- 4 mL/100 g.min) than untreated gliomas (26 +/- 7 mL/100 g.min). All examined molecular markers were decreased in OKN007-treated rat gliomas, compared with elevated levels in untreated rats. CONCLUSION: MRI assessment was successfully used to monitor a decrease in tumor growth, and corresponding alterations in ADC and perfusion rates in rat C6 gliomas treated with the anti-glioma agent, OKN007. (c) 2010 Wiley-Liss, Inc.
PURPOSE: To demonstrate that OKN007, a disulfonyl derivative of phenyl-tert-butyl nitrone (PBN), has anti-glioma activity in the clinically relevant C6 ratglioma model using multi-parametric magnetic resonance imaging. MATERIALS AND METHODS: Twenty-one rats were intracerebrally implanted with C6 cells and administered OKN007 or kept as controls. Animals were monitored with MRI at 7 Tesla (T), using morphologic, diffusion-weighted and perfusion imaging, followed by histology and Western blots of angiogenesis and inflammatory markers. RESULTS: OKN007 was found to decrease tumor volumes and increase survival. The glioma tissues of OKN007-treated rats were found to have longitudinal apparent diffusion coefficients (ADC(z)) of 0.76 +/- 0.06 x 10(-3) mm(2)/s, similar to the contralateral tissue and significantly smaller than untreated gliomas (0.97 +/- 0.13 x 10(-3) mm(2)/s). They had higher perfusion rates (66 +/- 4 mL/100 g.min) than untreated gliomas (26 +/- 7 mL/100 g.min). All examined molecular markers were decreased in OKN007-treated ratgliomas, compared with elevated levels in untreated rats. CONCLUSION: MRI assessment was successfully used to monitor a decrease in tumor growth, and corresponding alterations in ADC and perfusion rates in ratC6 gliomas treated with the anti-glioma agent, OKN007. (c) 2010 Wiley-Liss, Inc.
Authors: Stefano Tarantini; Peter Hertelendy; Zsuzsanna Tucsek; M Noa Valcarcel-Ares; Nataliya Smith; Akos Menyhart; Eszter Farkas; Erik L Hodges; Rheal Towner; Ferenc Deak; William E Sonntag; Anna Csiszar; Zoltan Ungvari; Peter Toth Journal: J Cereb Blood Flow Metab Date: 2015-07-15 Impact factor: 6.200
Authors: Robert A Floyd; Hugo C Castro Faria Neto; Guy A Zimmerman; Kenneth Hensley; Rheal A Towner Journal: Free Radic Biol Med Date: 2013-02-16 Impact factor: 7.376
Authors: Patricia Coutinho de Souza; Krithika Balasubramanian; Charity Njoku; Natalyia Smith; David L Gillespie; Andrea Schwager; Osama Abdullah; Jerry W Ritchey; Kar-Ming Fung; Debra Saunders; Randy L Jensen; Rheal A Towner Journal: J Magn Reson Imaging Date: 2015-04-29 Impact factor: 4.813
Authors: Rheal A Towner; David L Gillespie; Andrea Schwager; Debra G Saunders; Nataliya Smith; Charity E Njoku; Richard S Krysiak; Chelsea Larabee; Henna Iqbal; Robert A Floyd; David W A Bourne; Osama Abdullah; Edward W Hsu; Randy L Jensen Journal: Neuro Oncol Date: 2013-01-17 Impact factor: 12.300
Authors: Ines Batinic-Haberle; Artak Tovmasyan; Emily R H Roberts; Zeljko Vujaskovic; Kam W Leong; Ivan Spasojevic Journal: Antioxid Redox Signal Date: 2013-10-01 Impact factor: 8.401